Corcept executive exercises options and sells shares
Corcept Therapeutics executive Sean Maduck exercised options for 1,031 shares of common stock at $8.27 per share and sold the same 1,031 shares at a weighted average price of $114.5182 on August 10, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Corcept Therapeutics executive Sean Maduck exercised options for 1,031 shares of common stock at $8.27 per share and sold the same 1,031 shares at a weighted average price of $114.5182 on August 10, 2026. Following the option exercise, he held 95,650 stock options directly, and also holds various indirect positions through trusts and LLCs. The sale was executed under a Rule 10b5-1 trading plan adopted on December 8, 2025. His direct holdings include unvested restricted stock awards that vest one year after their respective grant dates.
Insider Trade Summary 10b5-1
Exercise and Sale: 1,031 shares ($110K approx. pre-tax spread)
Exercise and Sale
8 txns
Insider
Maduck Sean
Role
See Remarks
Sold
1,031 shs ($118K)
Approx. gross sale proceeds
$118K
Approx. exercise cost
$9K
Approx. pre-tax spread
$110K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock option (right to buy) F9 | 1,031 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 1,031 | $8.27 | $9K |
| Sale | Common Stock F2, F3, F1 | 1,031 | $114.5182 | $118K |
| holding | Common Stock F4 | -- | -- | -- |
| holding | Common Stock F5 | -- | -- | -- |
| holding | Common Stock F6 | -- | -- | -- |
| holding | Common Stock F7 | -- | -- | -- |
| holding | Common Stock F8 | -- | -- | -- |
Holdings After Transaction:
Stock option (right to buy) — 95,650 contracts (Direct);
Common Stock — 9,755 shares (Direct);
Common Stock — 109,717 shares (Indirect, See Footnote)
Footnotes (9)
- F1. Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- F2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.
- F3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.50 to $114.58 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- F4. Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
- F5. Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager.
- F6. Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
- F7. Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
- F8. Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
- F9. Fully exercisable.
Key Figures
Options exercised: 1,031 shares
Exercise price: $8.27 per share
Shares sold: 1,031 shares
+5 more
8 metrics
Options exercised
1,031 shares
Stock option (right to buy) exercised on August 10, 2026
Exercise price
$8.27 per share
Conversion or exercise price of options exercised for 1,031 shares
Shares sold
1,031 shares
Common Stock sale on August 10, 2026
Weighted average sale price
$114.5182 per share
Weighted average for 1,031 shares sold; individual prices $114.50–$114.58
Remaining stock options
95,650 options
Total stock options held directly following the reported option exercise
10b5-1 plan adoption date
December 8, 2025
Rule 10b5-1 trading plan governing the August 10, 2026 sale
Restricted stock award tranches
228; 205; 454; 615 shares
Unvested restricted stock awards from grants in 2025–2026 vesting after one year
Option expiration date
February 10, 2027
Expiration of the option from which 1,031 shares were exercised
Key Terms
Rule 10b5-1 plan, weighted average sale price, restricted stock awards, Grantor Retained Annuity Trust, +1 more
5 terms
Rule 10b5-1 plan regulatory
"This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average sale price financial
"Represents the weighted average sale price for the entire number of shares sold."
restricted stock awards financial
"Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person"
Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.
Grantor Retained Annuity Trust financial
"Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person"
A grantor retained annuity trust (GRAT) is an estate-planning tool where the person who creates the trust transfers assets into it but receives fixed cash payments (an annuity) from the trust for a set number of years; whatever remains after that term passes to designated beneficiaries. It matters to investors because it can shift future appreciation of assets out of the creator’s taxable estate—like putting an asset into a timed vending machine that pays you fixed amounts while any extra value that grows inside the machine goes to heirs with reduced gift or estate tax consequences.
pecuniary interest financial
"disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Corcept Therapeutics (CORT) executive Sean Maduck report in this Form 4?
Sean Maduck reported exercising 1,031 stock options at $8.27 and selling 1,031 common shares at a weighted average of $114.5182 on August 10, 2026, along with his remaining option and indirect holdings context.
How many Corcept Therapeutics (CORT) options does Sean Maduck hold after the transactions?
After exercising options on August 10, 2026, Sean Maduck directly holds 95,650 stock options. These options are reported as Stock option (right to buy) with an expiration date of February 10, 2027, following the 1,031-share exercise.
At what prices were Sean Maduck’s Corcept Therapeutics (CORT) transactions executed?
Maduck exercised options at a $8.27 per-share exercise price and sold 1,031 shares at a weighted average price of $114.5182 per share. The filing notes actual sale prices ranged from $114.50 to $114.58.
Was the Corcept Therapeutics (CORT) insider sale by Sean Maduck under a Rule 10b5-1 plan?
Yes. A footnote states the August 10, 2026 sale was made pursuant to a Rule 10b5-1 plan adopted by Sean Maduck on December 8, 2025, indicating the trades were pre-arranged under that plan.
What restricted stock awards does Sean Maduck hold at Corcept Therapeutics (CORT)?
His direct holdings include unvested restricted stock awards covering 228, 205, 454, and 615 shares from grants made in 2025–2026. 100% of the shares in each grant vest on the one-year anniversary of its grant date, subject to requirements.
What indirect Corcept Therapeutics (CORT) holdings are associated with Sean Maduck?
Indirect holdings are reported through entities including the Sean and Molly Maduck Living Trust, MMM 2025, LLC, two Grantor Retained Annuity Trusts, and Duckhill Capital, LLC, where he is trustee, member/manager, or president, with a pecuniary-interest disclaimer on Duckhill Capital.
AI-generated analysis. How Rhea-AI works. Not financial advice.
